Liver problems with Abbott Laboratories Inc.’s discontinued attention deficit drug Cylert and other generic versions are too dangerous for the U.S. market, the Food and Drug Administration said on Monday.

“The agency has concluded that the overall risk of liver toxicity from Cylert and generic pemoline products outweighs the benefits of this drug,” the FDA said in a warning posted on its Web site.

In March, Abbott said it would no longer make the drug due to declining sales, but consumer advocates had argued it was too dangerous to be sold.

 


Comments


View Comments / Leave a Comment

This post currently has 2 comments.
You can read the comments or leave your own thoughts.


    Last reviewed: By John M. Grohol, Psy.D. on 24 Oct 2005
    Published on PsychCentral.com. All rights reserved.

APA Reference
Grohol, J. (2005). Discontinued ADD drug too risky: FDA. Psych Central. Retrieved on November 27, 2014, from http://psychcentral.com/blog/archives/2005/10/24/discontinued-add-drug-too-risky-fda/

 

Recent Comments
  • ek_ladki: “Genshai”? There is no such word in the Hindi language.
  • amandaundialed.: I completely agree with you. I’m thankful that I have read this, and that other people...
  • amandaundialed.: Amazing advice. You should be the administrator of most sites. Thank you very much; I found your...
  • amandaundialed.: :) thank you
  • amandaundialed.: But … What I think I read was that you can ask a psychologist for a rate ;whilst not free, is...
Subscribe to Our Weekly Newsletter


Find a Therapist
Enter ZIP or postal code



Users Online: 8828
Join Us Now!